Avid Bioservices' stock plummeted 30% post-earnings; Q3 revenue fell 11%, with significant drops in gross margin and operating income. Announced planned $160 million 7.00% Convertible Senior Notes; ...
--Avid Bioservices, Inc., a dedicated biologics contract development and manufacturing organization working to improve patient lives by providing high quality development and manufacturing services to ...
TUSTIN, Calif., July 02, 2024 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ: CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient ...
TUSTIN, Calif., Dec. 10, 2024 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ: CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient ...
-- Signed $35 Million in Net New Business Orders Resulting in a Backlog of $199 Million-- “Despite the challenges of the first half of fiscal 2024, our current backlog and pipeline position us well to ...
-- Recorded First Quarter Revenue of $40.2 Million -- -- Signed $66 Million in Net New Business, Resulting in Backlog of $219 Million -- -- Maintained FY2025 Revenue Guidance of Between $160 Million ...
TUSTIN, Calif., Sept. 07, 2023 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback